Loading institutional data...
Loading institutional data...
Held by 327 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $46.47 today, the market must believe free cash flow compounds 1.7%/yr for a decade (off $243M normalized FCF).
The market's 1.7% is more conservative than its 9-yr track record.
2-stage DCF · 0.05B shares (market data) · net debt $930M
mean 6.8% · volatility σ 14% · implied rate exceeded in 5/9 yrs
Central path = implied 1.7%/yr growth; shaded band = ±1σ (14%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $156M buybacks = $156M returned on $246M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 7%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $64M covers the $0 due within a year 63868000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2026-03-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~0.2% on $992M of debt. Interest last disclosed in FY2025 (no longer broken out).
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.09B 100.0% | $1.14B 100.0% | $1.13B 100.0% | $1.13B 100.0% | $1.09B 100.0% | $943.4M 100.0% | $963.0M 100.0% | $975.8M 100.0% | $1.04B 100.0% | $882.1M 100.0% |
| Cost of Revenue | $493.1M 45.3% | $503.3M 44.2% | $500.9M 44.5% | $502.4M 44.6% | $466.2M 42.9% | $395.9M 42.0% | $410.8M 42.7% | $420.2M 43.1% | $464.7M 44.6% | $381.8M 43.3% |
| Gross Profit | $595.6M 54.7% | $634.5M 55.8% | $624.4M 55.5% | $625.3M 55.4% | $620.6M 57.1% | $547.5M 58.0% | $552.2M 57.3% | $555.6M 56.9% | $576.5M 55.4% | $500.3M 56.7% |
| Selling, General & Admin | $116.4M 10.7% | $108.2M 9.5% | $106.2M 9.4% | $107.4M 9.5% | $107.5M 9.9% | $83.1M 8.8% | $89.1M 9.3% | $89.8M 9.2% | $85.4M 8.2% | $89.1M 10.1% |
| Total Operating Expenses | $286.2M 26.3% | $297.7M 26.2% | $282.0M 25.1% | $647.7M 57.4% | $290.7M 26.8% | $250.1M 26.5% | $261.1M 27.1% | $488.1M 50.0% | $361.0M 34.7% | $294.6M 33.4% |
| Operating Income | $309.4M 28.4% | $336.8M 29.6% | $342.4M 30.4% | -$22.4M -2.0% | $329.9M 30.4% | $297.4M 31.5% | $291.2M 30.2% | $67.5M 6.9% | $215.5M 20.7% | $205.6M 23.3% |
| Interest Expense | — | $1.8M 0.2% | $5.2M 0.5% | $4.4M 0.4% | $64.3M 5.9% | $82.3M 8.7% | $96.2M 10.0% | $105.1M 10.8% | $106.3M 10.2% | $93.5M 10.6% |
| Interest & Investment Income | — | — | — | — | — | — | $342K 0.0% | $217K 0.0% | $388K 0.0% | $203K 0.0% |
| Other Income (Expense), net | -$9.6M -0.9% | -$5.0M -0.4% | $756K 0.1% | -$2.3M -0.2% | -$1.1M -0.1% | $1.4M 0.1% | -$1.6M -0.2% | -$476K -0.0% | $392K 0.0% | -$30K -0.0% |
| Pretax Income | $257.5M 23.7% | $284.2M 25.0% | $276.0M 24.5% | -$93.9M -8.3% | $262.5M 24.1% | $204.1M 21.6% | $191.2M 19.8% | -$38.1M -3.9% | $107.1M 10.3% | $110.8M 12.6% |
| Income Tax Expense | $67.2M 6.2% | $69.6M 6.1% | $66.7M 5.9% | -$11.6M -1.0% | $57.1M 5.3% | $39.4M 4.2% | $48.9M 5.1% | -$2.3M -0.2% | -$232.5M -22.3% | $41.5M 4.7% |
| Net Income | $190.3M 17.5% | $214.6M 18.9% | $209.3M 18.6% | -$82.3M -7.3% | $205.4M 18.9% | $164.7M 17.5% | $142.3M 14.8% | -$35.8M -3.7% | $339.6M 32.6% | $69.4M 7.9% |
| Per Share | ||||||||||
| EPS (Basic) | $3.93 | $4.32 | $4.21 | $-1.65 | $4.09 | $3.28 | $2.81 | $-0.69 | $6.40 | $1.31 |
| EPS (Diluted) | $3.91 | $4.29 | $4.17 | $-1.65 | $4.04 | $3.25 | $2.78 | $-0.69 | $6.34 | $1.30 |
| Weighted Avg Shares (Basic) | 48.5M | 49.7M | 49.8M | 49.9M | 50.3M | 50.2M | 50.7M | 52.1M | 53.1M | 53.0M |
| Weighted Avg Shares (Diluted) | 48.7M | 50.1M | 50.2M | 49.9M | 50.8M | 50.6M | 51.1M | 52.1M | 53.5M | 53.4M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 15-yr range · 8th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 15-yr history.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.9× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 43.1 | 42.7 | 42.0 | 42.9 | 44.6 | 44.5 | 44.2 | 45.3 |
| Gross Profit | 56.9 | 57.3 | 58.0 | 57.1 | 55.4 | 55.5 | 55.8 | 54.7 |
| SG&A | 9.2 | 9.3 | 8.8 | 9.9 | 9.5 | 9.4 | 9.5 | 10.7 |
| Operating Income | 6.9 | 30.2 | 31.5 | 30.4 | -2.0 | 30.4 | 29.6 | 28.4 |
| Income Tax | -0.2 | 5.1 | 4.2 | 5.3 | -1.0 | 5.9 | 6.1 | 6.2 |
| Net Income | -3.7 | 14.8 | 17.5 | 18.9 | -7.3 | 18.6 | 18.9 | 17.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PBH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| PBH | $2.2B | 11.9× | 9.2× | 2.0× | -4.3% | 54.7% | 17.5% | 10.1% | 6.6% | 2.9× | 327 |
Peers = companies sharing PBH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.